Floatz logo

Epirubicin

Gliomas, Malignant

Essen BiotechPhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Gliomas, Malignant cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Essen Biotech
Phase 1/2CCC
on-01
Beijing Neurosurgical Institute
Phase 1/2CCC
Onf
Beijing Neurosurgical Institute
Phase 1/2CCC
TIL
Essen Biotech
Phase 1/2CCC
ik-595
Ikena Oncology
Phase 1CC
5-FLUOROCYTOSINE
Tocagen Inc.
Phase 1CC
Vocimagene Amiretrorepvec
Tocagen Inc.
Phase 1C

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →